Lexicon Pharmaceuticals, Inc. (LXRX) Q2 FY26 Earnings Call

Two late-stage sotagliflozin milestones are approaching, but approval and clinical outcomes remain unproven.

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-08-06
Length39 minutes
EPS$-0.06
EPS consensus$-0.06
Revenue$692000.00

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

All LXRX earnings ยท Back to LXRX overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.